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Abstract
Background: Progress in dengue vaccine development has been hampered by limited understanding of protective
immunity against dengue virus infection. Conventional neutralizing antibody titration assays that use FccR-negative cells do
not consider possible infection-enhancement activity. We reasoned that as FccR-expressing cells are the major target cells of
dengue virus, neutralizing antibody titration assays using FccR-expressing cells that determine the sum of neutralizing and
infection-enhancing activity, may better reflect the biological properties of antibodies in vivo.
Methods and Findings: We evaluated serum samples from 80 residents of a dengue endemic country, Malaysia, for
neutralizing activity, and infection-enhancing activity at 1:10 serum dilution by using FccR-negative BHK cells and FccR-
expressing BHK cells. The serum samples consisted of a panel of patients with acute DENV infection (31%, 25/80) and a
panel of donors without acute DENV infection (69%, 55/80). A high proportion of the tested serum samples (75%, 60/80)
demonstrated DENV neutralizing activity (PRNT50$10) and infection-enhancing activity. Eleven of 18 serum samples from
patients with acute secondary DENV infection demonstrated neutralizing activity to the infecting serotype determined by
using FccR-negative BHK cells (PRNT50$10), but not when determined by using FccR-expressing cells.
Conclusion: Human serum samples with low neutralizing activity determined by using FccR-negative cells showed DENV
infection-enhancing activity using FccR-expressing cells, whereas those with high neutralizing activity determined by using
FccR-negative cells demonstrate low or no infection-enhancing activity using FccR-expressing cells. The results suggest an
inverse relationship between neutralizing antibody titer and infection-enhancing activity, and that neutralizing activity
determined by using FccR-expressing cells, and not the activity determined by using FccR-negative cells, may better reflect
protection to DENV infection in vivo.
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Introduction
Dengue fever (DF) and dengue hemorrhagic fever (DHF) is
caused by infection with dengue virus (DENV), a flavivirus, which
consists of four serotypes (DENV-1, DENV-2, DENV-3 and
DENV-4). DENV affects up to 100 million people annually living
in the tropics and sub-tropical areas. Clinical manifestations of
DENV infection ranges from asymptomatic and relatively mild
dengue fever (DF), to severe, life-threatening illness, dengue
hemorrhagic fever (DHF) and dengue shock syndrome (DSS)
[1,2]. In endemic regions, the risk for developing severe infection
was speculated to be higher as compared to non-endemic regions
due to the higher possibility of secondary exposure to heterologous
DENV serotypes [3,4]. The number of dengue patients has
increased in Malaysia over the past 10 years with 7,103 cases and
45 deaths in 2000, to 41,486 cases and 88 deaths in 2009, to,
46,171 cases and 134 deaths in 2010 [5,6]. All four DENV
serotypes co-circulate in Malaysia [7,8]. High prevalence of severe
dengue virus infections and dengue-related deaths in recent years
is speculated to be associated to rapid urbanization and global
travel, leading to the spread of dengue virus, and thus to higher
prevalence of infected individuals [9–11].
Primary infection with one DENV serotype does not confer
protection to infection with a heterologous serotype [12,13].
Epidemiological studies have demonstrated that DHF occurs at a
higher rate in secondary infection than in primary infection [14–
17]. DENV sub-neutralizing, infection-enhancing antibodies
induced during primary infection is speculated to play a central
role in the pathogenesis of DHF [18–21]. During secondary
infection, sub-neutralizing antibodies form infectious immune-
complexes with DENV, resulting in higher levels of viral progeny
in FccR-expressing cells, a phenomenon known as antibody-
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8dependent enhancement (ADE) [22,23]. It has been speculated
that ADE may play a role not only in causing DHF but in
worsening a spectrum of DENV illness [24].
We previously demonstrated that higher neutralizing antibody
titers were detected using FccR-negative BHK cells as compared
to FccR-expressing BHK cells [25]. In the present study, we
examined DENV infection-enhancing activity in serum samples
with varying levels of DENV neutralizing activity using FccR-
expressing BHK cells.
Materials and Methods
Serum samples
Eighty serum samples obtained from 80 residents in Perak,
Malaysia were used in the study. Perak is located in north-western
region of Peninsular Malaysia, and is endemic for dengue, and
other flavivirus infections [26–28]. Incidence of DENV infection
in Perak was 2,288 in 2010, 2,734 in 2009, and, 4,119 in 2008 [6].
The serum samples were collected in 2008 and were provided by
National Public Health Laboratory, Malaysia. Characteristics of
the patient population sampled are summarized in Table 1.
Ethics statement
The study protocol was approved by the ethics committee of
the National Institute Infectious Diseases, Japan (Reference
no. 210). Patients were de-identified and study data was analyzed
anonymously.
Dengue diagnostics
Patient serum samples used in the present study were examined
for the presence of dengue viral RNA by reverse-transcriptase
polymerase chain reaction (RT-PCR), and NS1 antigenby enzyme-
linked immunosorbant assay (ELISA). Viral RNA was extracted
using High Pure RNA extraction kit (Roche Diagnostics, Germany)
and DENV serotypes were determined by serotype-specific reverse
transcriptase polymerase chain reaction (RT-PCR) [29]. For
serological tests, serum samples were heat-inactivated at 56uC for
30 minutes beforeuse. Detection of the NS1 antigen was performed
using Platelia Dengue NS1 Antigen (Bio-Rad Laboratories, France)
according to manufacturers’ instructions. After reaction was ter-
minated, optical density readings (OD) were obtained with a
spectrophotometer at wavelengths of 450 nm/620 nm and the
index ofeachsamplewascalculated with thefollowingformula:OD
of samples/OD of calibrators. The index value of each sample was
interpreted accordingtomanufacturer’sinstructions;indexvaluesof
,0.9, 0.9–1.1, and, .1.1 were considered negative, equivocal, and
positive, respectively [30].
Viruses and cell lines
Denguevirustype1(DENV-1),01-44-1HuNIIDstrain(GenBank
accession no. AB111070), dengue virus type 2 (DENV-2) D2/Hu/
OPD030NIID/2005 strain (GenBank accession no. AB219135),
dengue virus type 3 (DENV-3) CH53489 strain (GenBank accession
no. DQ863638), and, denguevirus type4 (DENV-4)TVP360strain
were used. BHK cells, a hamster kidney cell line (Japan Health
Science Research Resources Bank, Japan) and FccR-expressing
BHK cells were used. Cells were cultured in Eagle’s Minimum
Essential Medium (EMEM) (Sigma, USA), supplemented with heat
inactivated 10% fetal calf serum (FCS, Sigma) at 37uCi n5 %C O 2.
FccR-expressing BHK cells were cultured in EMEM (Sigma),
supplemented with heat inactivated 10% FCS (Sigma) and 0.5 mg/
ml neomycin (G418, PAA Laboratories GmbH, Austria) at 37uCi n
5% CO2 [25].
Plaque reduction neutralization test (PRNT)
Heat-inactivated human serum samples were serially diluted 2-
folds from 1:5 to 1:1250 with EMEM/2% FCS. As the amount
of serum samples was limited, two replicates were tested for each
of the serum samples to four dengue serotype. Virus-antibody
mixture was prepared by mixing 25 ml of DENV-1, DENV-2,
DENV-3, or, DENV-4 at titers of 2000 PFU/ml with 25 mlo f
serum samples serially diluted 2 folds from 1:5 to 1:1250. For
Table 1. Characteristics of the study populations.
Patient Characteristics
a Number (n)
Number of patients (samples collected) 80 (80)
Category of infection
Primary acute DENV infection
b
DENV-1 5
DENV-3 2
Secondary acute DENV infection
c
DENV-1 7
DENV-3 11
Others
d 55
aHistory of previous flavivirus infection of each patient was not determined.
bDENV infection was confirmed as described in Materials and Methods. Primary
DENV infection was defined as serum samples that were negative for
neutralizing to all of the four DENV serotypes at serum dilution of 1:10.
cDENV infection was confirmed as described in Materials and Methods.
Secondary DENV infection was defined as serum samples that were positive for
neutralizing to any of the four DENV serotypes at serum dilution of 1:10.
dA total of 55 serum samples from 55 non acute dengue patients were used.
Serum samples were derived from the following categories: DENV genome
and NS1 antigen negative (n=34), and chikungunya virus (CHIKV) genome
positive (n=21).
doi:10.1371/journal.pntd.0001536.t001
Author Summary
Dengue has become a major international public health
concern in recent decades. There are four dengue virus
serotypes. Recovery from infection with one serotype
confers life-long protection to the homologous serotype
but only partial protection to subsequent infection with
other serotypes. Secondary infection with a serotype
different from that in primary infection increases the risk
of development of severe complications. Antibodies may
play two competing roles during infection: virus neutral-
ization that leads to protection and recovery, or infection-
enhancement that may cause severe complications.
Progress in vaccine development has been hampered by
limited understanding on protective immunity against
dengue virus infection. We report the neutralization
activity and infection-enhancement activity in individuals
with dengue in Malaysia. We show that infection-
enhancement activity is present when neutralizing activity
is absent or low, and cross-reactive neutralizing activity
may be hampered by infection-enhancing activity. Con-
ventional assays for titration of neutralizing antibody do
not consider infection-enhancement activity. We used an
alternative assay that determines the sum of neutralizing
and infection-enhancement activity in sera from dengue
patients. In addition to providing insights into antibody
responses during infection, the alternative assay provides a
new platform for the study of immune responses to
vaccine.
ADE Activity in Sera with Neutralizing Activity
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25 ml of DENV-1, DENV-2, DENV-3, or, DENV-4 strains at
titers of 2000 PFU/ml with 25 ml of EMEM supplemented with
10% FCS. After incubation at 37uC for 60 minutes, 50 ml of virus-
antibody mixture was inoculated on FccR-negative BHK and
FccR-expressing BHK monolayers in 12-well plates. The plates
were then incubated for 60 minutes at 37uCi n5 %C O 2. After
virus absorption, the cells were washed once with 1 ml of EMEM
(Sigma) and overlaid with 1 ml EMEM (Nissui Pharmaceutical,
Japan) containing 2% FCS (Sigma) and 1% methylcellulose (Wako
Pure Chemical Industries, Japan). The plates were incubated at
37uCi n5 %C O 2 for 5–7 days, when plaque formation could be
confirmed by naked eye. Cells were then fixed with 10% formalin
(Wako Pure Chemical Industries) and stained with methylene blue
(Wako Pure Chemical Industries). Number of plaques was counted
with naked eye. Plaque-reduction neutralizing test (PRNT50) end
points are expressed as the last serum dilution showing a 50% or
greater reduction in plaque counts as compared to the number of
plaques determined from wells of cells infected in the absence of
antibodies [31].
Antibody-dependent enhancement (ADE) assay
For enhancement assay against 4 DENV serotypes, 25 ml serum
samples diluted at 1:5 with EMEM/2% FCS were used. Virus-
antibody mixture was prepared by mixing 25 ml of DENV-1,
DENV-2, DENV-3, or, DENV-4 strains at titers of 1000–
2000 PFU/ml with 25 ml of 1:5 diluted serum samples and
incubated at 37uC for 60 minutes. For negative controls, virus
mixture was prepared by mixing 25 ml of DENV-1, DENV-2,
DENV-3, or, DENV-4 strains at titers of 1000–2000 PFU/ml
with 25 ml of 2% FCS/EMEM and incubated at 37uC for
60 minutes. Fifty microliters of the virus-antibody mixture was
then applied to FccR-expressing BHK monolayers in 12-well
plates. The plates were then incubated for 60 minutes at 37uCi n
5% CO2. After virus absorption, the cells were washed with 1 ml
of EMEM and overlaid with 1 ml EMEM containing 2% FCS and
1% methylcellulose. The plates were incubated at 37uCi n5 %
CO2 for 5 days. Cells were then fixed with 10% formalin and
stained with methylene blue. Plaques were counted with naked
eye. Fold enhancement values were determined using the
following ratio: (mean plaque count at 1:10 serum dilution)/
(mean plaque count in the absence of human serum samples,
negative control). The sum of the mean of the negative control
plus two times of the standard deviation (SD) value obtained from
4 wells of negative control was used as cut-off to differentiate
enhancing and non-enhancing activity [32,33]. Enhancing activity
was defined as positive when values are greater than the mean
plaque count in the absence of human serum samples plus a
greater than 2 times SD.
Results
Neutralizing and infection-enhancing activities of serum
samples collected in Perak, Malaysia
Eighty serum samples were tested for the presence of neutralizing
antibody to each of the four DENV serotypes by using BHK cells
(Table 1). Neutralizing antibody (PRNT50$10) was detected in
69%(55/80)to DENV-1,60%(48/80) toDENV-2,56%(45/80)to
DENV-3 and, 20% (16/80) to DENV-4. Of the 80 samples, 12
samples and 13 samples were obtained from patients with acute
DENV-1 and DENV-3 infections, respectively (Table 1). Neutral-
izing activity to DENV-1 was detected in 58% (7/12) of the DENV-
1 infected patients and that to DENV-3 was detected in 62% (8/13)
of the DENV-3 infected patients. In contrast, enhancing-activity to
DENV-1 was detected in 33% (4/12) of the DENV-1 infected
patients and that to DENV-3 was detected in 61% (8/13) of the
DENV-3patients (Table2).Five DENV-1infected patients and two
DENV-3 infected patients demonstrated neither neutralizing nor
infection-enhancing activity to any of the four DENV serotypes
(TableS4).Four(58%)ofthe 7 serumsamplesfrom acutesecondary
DENV-1 infected patients demonstrated infection-enhancing
activities to DENV-1 serotype and similarly, 8 (73%) of 11 serum
samples from acute secondary DENV-3 infected patients enhanced
DENV-3 infection. The results indicate that serum samples from
dengue patients and non-dengue patients in dengue endemic
region, Malaysia, possess neutralizing and infection-enhancing
activities (Table S1, Table S2). The history of past dengue infections
of each ofthepatients washowever, notknown.Because Malaysiais
endemic for dengue infection, and some of the serum samples
exhibited high levels of neutralizing antibody titers to DENV, it is
highly likely that the patients with high neutralizing antibody
activity has been previously exposed to DENV infection.
Table 2. Neutralizing and infection-enhancement activities against each of the 4 serotypes of dengue virus.
Activity
% Prevalence of neutralizing or enhancing activity to DENV serotypes
(number positive/total number)
DENV-1 DENV-2 DENV-3 DENV-4
Neutralizing antibody (PRNT50 $1:10) 69 (55/80) 60 (48/80) 56 (45/80) 20 (16/80)
DENV-1 patient
a 58 (7/12) 67 (8/12) 17 (2/12) 8 (1/12)
DENV-3 patient
a 69 (9/13) 69 (9/13) 62 (8/13) 15 (2/13)
Others
b 71 (39/55) 56 (31/55) 64 (35/55) 69 (38/55)
Enhancing activity
c 26 (21/80) 26 (21/80) 30 (24/80) 73 (58/80)
DENV-1 patient
a 33 (4/12) 25 (3/12) 42 (5/12) 75 (9/12)
DENV-3 patient
a 38 (5/13) 8 (1/13) 62 (8/13) 85 (11/13)
Others
b 22 (12/55) 31 (17/55) 25 (14/55) 69 (38/55)
aSerum samples obtained from DENV patients. Infecting DENV serotype was determined by RT-PCR.
bOthers consist of a total of 55 serum samples from 55 non acute dengue patients. Serum samples were derived from the following categories: DENV genome and NS1
antigen negative (n=34), and chikungunya virus (CHIKV) genome positive (n=21).
cPositive infection-enhancement activity was defined as fold-enhancement values greater than cut-off plus a 2 times SD (or cut-off+2SD) in the mean plaque count in
the presence of human serum samples.
doi:10.1371/journal.pntd.0001536.t002
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serotypes determined by using FccR-negative BHK cells
and FccR-expressing BHK cells
The 18 samples derived from acute secondary dengue patients
which demonstrated both neutralizing and infection-enhancing
activities were examined for neutralizing antibody titers to each
of the 4 DENV serotypes. The serum samples were from 7 acute
secondary DENV-1 patients and 11 acute secondary DENV-3
patients (Table 1). Using FccR-negative BHK cells, 7 serum
samples possessed neutralizing antibody titers only to DENV-2 and
11 samples showed neutralizing antibody to more than one serotype
(Table 3, Table S3). All the serum samples except one (17 of 18)
demonstrated neutralizing antibody titers to DENV-2 at titers of
1:10 to 1:1280. Using FccR-positive BHK cells, 13 serum samples
obtained from patients with DENV-1 or DENV-3 infection
possessed neutralizing antibody titers only to DENV-2 (1:10 to
1:160), and 2 samples possessed neutralizing antibody titers only to
DENV-1 (1:10 to 1:20). Some of the non acute dengue patients
(serum sample no. 23, 28, 30, 38, 73, 74, 77, 78, 79, Table 4)
exhibited heterotypic neutralizing activity using BHK cells but
monotypicneutralizingactivityusingFccR-expressingcells,asthose
observed in patients with acute secondary dengue infection
(Table 3).
Interestingly, serum samples from patients with acute secondary
infection (#46, 49, 56, 40, 42, 43, 44, 45, 52, and 54)
demonstrated neutralizing antibody titers of 1:10–1:80 to the
infecting serotype as determined using BHK cells, but these serum
samples showed no neutralizing antibody titers to the infecting
serotype as determined using FccR-expressing BHK cells (Table 3).
The results indicate that neutralizing antibody titers determined
by using FccR-expressing BHK cells were lower than those
determined by using FccR-negative BHK cells, and that for some
Table 3. Level of neutralizing activity in serum samples obtained from patients with secondary acute dengue infection and from
selected non acute dengue patients against each of the 4 DENV serotypes.
Patient
a
Patient
no Neutralizing antibody titer to DENV (PRNT50)
BHK cells FccR-expressing BHK cells
DENV-1 DENV-2 DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4
Infecting serotype: DENV-1
b 46 80 40 20 20 ,10 10 ,10 ,10
47 ,10 20 ,10 ,10 ,10 ,10 ,10 ,10
48 ,10 10 ,10 ,10 ,10 ,10 ,10 ,10
49 10 1280 ,10 ,10 ,10 160 ,10 ,10
56 10 10 ,10 ,10 ,10 ,10 ,10 ,10
57 ,10 40 ,10 ,10 ,10 40 ,10 ,10
58 ,10 320 ,10 ,10 ,10 10 ,10 ,10
Infecting serotype: DENV-3
b 39 80 ,10 10 ,10 20 ,10 ,10 ,10
40 20 160 20 ,10 ,10 40 ,10 ,10
41 ,10 80 ,10 ,10 ,10 20 ,10 ,10
42 20 640 40 40 ,10 80 ,10 ,10
43 80 40 20 ,10 10 ,10 ,10 ,10
44 10 320 10 ,10 ,10 80 ,10 ,10
45 40 320 40 ,10 ,10 80 ,10 ,10
52 20 20 10 ,10 ,10 10 ,10 ,10
53 ,10 160 ,10 ,10 ,10 40 ,10 ,10
54 80 1280 40 10 ,10 80 ,10 ,10
Non acute DENV
c 15 20 ,10 10 ,10 ,10 ,10 ,10 ,10
23 20 160 160 ,10 ,10 80 ,10 ,10
28 40 ,10 40 10 20 ,10 ,10 ,10
30 40 40 20 10 ,10 20 ,10 ,10
38 ,10 320 ,10 ,10 ,10 80 ,10 ,10
73 80 ,10 20 ,10 20 ,10 ,10 ,10
74 40 ,10 80 10 20 ,10 ,10 ,10
77 80 10 10 ,10 40 ,10 ,10 ,10
78 10 80 10 ,10 ,10 40 ,10 ,10
79 10 10 160 ,10 ,10 ,10 40 ,10
aInfecting serotype indicates the DENV serotype detected in the serum sample as determined by RT-PCR.
bNeutralizing titers (PRNT50) to each of the 4 DENV serotypes for five DENV-1 patients and for two DENV-3 patients were less than 10 (PRNT50,10) by using FccR-
negative BHK cells and FccR-expressing BHK cells and the results were not included in Table 3. Neutralizing antibody titer to 4 DENV serotypes were determined by a
conventional PRNT method using FccR-negative BHK cells and FccR-expressing BHK cells as indicated in Materials and Methods.
cNeutralizing antibody titers were determined for samples from selected non acute dengue patients.
doi:10.1371/journal.pntd.0001536.t003
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using FccR-negative BHK cells, but not by using FccR-expressing
BHK cells. Major target cells of DENV in vivo are FccR-
expressing cells such as monocyte-lineage cells [34–37]. The
results suggest that the titers determined by using FccR-expressing
BHK cells may, thus, reflect actual biological activities of
antibodies in vivo.
Enhancing activity to 4 DENV serotypes in serum samples
with neutralizing activity
Fold-enhancement to DENV-1 ranged from 0.7–5.6; DENV-2,
,0.1–2.1, DENV-3, 0.9–4.9, and DENV-4, 1.1–7.0 with serum
sample from patients with infecting serotype of DENV-1. Fold-
enhancement to DENV-1 ranged from ,0.1–5.5; DENV-2,
,0.1–2.3; DENV-3, 0.6–6.7, and DENV-4, 0.9–7.1 with serum
samples from patients with infecting serotype of DENV-3 (Table 4,
Table S3). Some of the samples from non acute dengue patients
also exhibited enhancing activity to DENV (Table S1).
The results indicate that sera from patients with DENV
infection possess the ability to enhance the infection by the
infecting serotype. The ability of serum samples with DENV
neutralizing activity to enhance each of the 4 DENV serotypes at
1:10 serum dilution was analyzed (Figure 1). Serum samples with
neutralizing titers of $1:10 determined by using BHK cells
demonstrated lower levels of fold-enhancement to the homotypic
serotypes. Fold enhancement to DENV-1 of serum samples with
DENV-1 neutralizing antibody (NA) titer of $1:10 was 0.860.9
versus DENV-1 NA titer ,1:10=4.561.6 (P,0.01). Fold
infection-enhancement to DENV-2 using serum samples with
DENV-2 neutralizing antibody (NA) titers of $1:10 was 0.660.9,
while that of samples with DENV-2 NA titers ,1:10 was 1.961.1
(P,0.01). Fold enhancement to DENV-3 of serum samples with
DENV-3 neutralizing antibody (NA) titer of $1:10 was 0.961.1,
while DENV-3 NA titers ,1:10=3.962.1 (P,0.01). Fold enhan-
cement to DENV-4 of serum samples with DENV-4 neutralizing
antibody (NA) titer of $1:10 was 3.662.0, while that of samples
with DENV-4 NA titers ,1:10 was 4.961.9 (P=0.02) (Figure 1).
Serum samples with high levels of neutralizing activity to DENV-2
(40, 42, 44, 49, 54 and 58) exhibited peak fold enhancement
ranging from 5.8–7.6 at higher serum dilutions of 1:100–1:1000
(Figure 2).
Of the 55 serum samples from non acute dengue patients, 42
exhibited infection-enhancement activity to DENV (Table S1).
Enhancement activities against DENV-1 and DENV-3 using
serum samples obtained from 7 patients with acute DENV-1
infection (mean fold-enhancement=3.1, P=0.02, and mean fold-
enhancement=3.2, P=0.02 respectively) were significantly higher
than to those of samples from non-acute DENV patients with
multitypic neutralizing activity to $3 DENV serotypes (mean fold-
enhancement=0.6 to DENV-1, mean fold-enhancement=0.8
to DENV-3). Similarly, enhancement activities against DENV-3
of samples from 11 patients with acute DENV-3 infection (mean
fold-enhancement=2.4, P=0.04) were higher than those of
samples from non acute DENV patients with multitypic neu-
tralizing activity to $3 DENV serotypes (Table S5).
Using serum samples at 1:10 dilution, neutralizing activities
were higher in samples from patients with multitypic neutralizing
activity to $3 DENV serotypes (mean percentage of DENV-1
plaque reduction=92%, DENV-3 plaque reduction=92%) than
in those from patients with acute secondary DENV-1 infection
(DENV-1 plaque reduction=43%, P,0.01; DENV-3 plaque
reduction=34%, P,0.01) and, than in those from patients with
acute secondary DENV-3 infection (DENV-1 plaque reduc-
tion=63%, P=0.02; DENV-3 plaque reduction=55%, P,0.01)
(Table S6).
Neutralizing titers were higher in samples from non acute
dengue patients with neutralizing activity to multitypic DENV
than in those from patients with acute primary and secondary
DENV infection. In contrast, enhancing activity was significantly
lower in non acute dengue patients with neutralizing activity to
multitypic DENV than in those from patients with acute
secondary DENV infection (Table S5). The results suggest that
Table 4. Dengue virus enhancement activities in serum
samples obtained from patients with secondary dengue
infection and from selected non acute dengue patients.
Patient
a
Patient
No. Fold enhancement
b
DENV-1 DENV-2 DENV-3 DENV-4
Infecting serotype:
DENV-1
46 0.7 0.1 0.9 5.6
47 5.6
c 2.1 5.1 1.1
48 4.7 2.0 5.3 4.4
49 1.2 ,0.1 1.0 2.0
56 2.8 1.6 4.2 6.9
57 1.2 ,0.1 1.5 4.7
58 5.3 ,0.1 4.9 6.0
Infecting serotype:
DENV-3
39 ,0.1 2.3 1.5 6.1
40 1.9 ,0.1 1.1 4.6
41 5.5 ,0.1 5.7 6.5
42 0.6 ,0.1 1.7 1.4
43 0.5 0.9 1.9 5.3
44 1.5 ,0.1 4.3 7.3
45 0.7 ,0.1 0.8 5.9
52 1.5 ,0.1 1.0 0.9
53 5.2 0.2 1.4 4.7
54 0.8 ,0.1 2.0 5.0
55 5.2 0.2 6.7 6.9
Non acute DENV
d 15 1.0 4.1 4.3 5.4
23 2.5 ,0.1 1.3 4.4
28 0.2 2.4 4.1 5.5
30 3.2 0.1 2.5 6.1
38 5.1 ,0.1 6.3 5.6
73 ,0.1 1.5 4.3 7.3
74 ,0.1 1.2 1.1 2.5
77 ,0.1 1.9 1.3 6.7
78 1.7 ,0.1 1.3 4.7
79 1.8 1.4 ,0.1 6.6
aInfecting serotype indicates the DENV serotype detected in the serum sample
as determined by RT-PCR.
bFold enhancement values are enhancement ratio calculated by the fornula:
mean plaque count at 1:10 serum dilution/plaque count without addition of
serum using FccR-expressing BHK cell lines.
cUnderline indicates positive infection-enhancing activity. Positive infection-
enhancing activity is defined as fold-enhancement value greater than cut-off
value plus 2 times SD in the mean plaque count in the presence of human
serum samples as compared to the cut-off value. Cut-off value was determined
in the absence of serum.
dSerum samples obtained from selected non acute dengue patients.
doi:10.1371/journal.pntd.0001536.t004
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low levels of infection-enhancing activity to respective serotypes
at low serum dilutions. In contrast, serum samples without neu-
tralizing activity possess high levels of enhancing activity.
Discussion
The relationship between neutralizing activity determined using
FccR-negative cells and infection-enhancing activity determined
using FccR-expressing cells was examined in the present study.
We determined that a high proportion of the serum samples from
residents of a DENV endemic country, Malaysia, possessed
DENV neutralizing and infection-enhancing activity (75%, 60/
80; Table 2). The neutralizing antibody titers were higher when
determined by using FccR-negative cells than when determined by
using FccR-expressing cells (Table 3). Mammalian cells such as
Vero cells and BHK cells are commonly used in plaque reduction
neutralizing tests [39]. However, in the absence of FccR, these
cells exclusively detect neutralizing antibody titers. Other
investigators have suggested that the use of FccR-expressing cells,
Figure 1. Infection-enhancement activity in serum samples with neutralizing activity to each of the four DENV serotypes. Sixty serum
samples exhibiting neutralizing activity to DENV were analyzed for presence of infection-enhancement activity to each of the four DENV serotypes:
(A) DENV-1, (B) DENV-2, (C) DENV-3 and, (D) DENV-4. Infection-enhancement activity to each DENV serotype was determined by using FccR-
expressing cells by the formula: (mean plaque count at 1:10 serum dilution)/(mean plaque count in the absence of human serum samples), and
expressed as fold enhancement to each DENV serotype. Closed bars indicate serum samples with neutralizing titer PRNT50$10 to the indicated DENV
serotype and open bars indicate serum samples with neutralizing titer PRNT50,10 as determined using FccR-negative BHK cells. (*) indicates P,0.05.
doi:10.1371/journal.pntd.0001536.g001
Figure 2. Infection-enhancement activity in serum samples with neutralizing activity to DENV-2. Six serum samples with high
neutralizing activity to DENV-2 at 1:10 serum dilutions were tested for presence of infection-enhancement activity to DENV-2 at serum dilutions of
1:10 to 1:10
6. (A) serum sample #40, (B) #42, (C) #44 (D) #49, (E) #54 and, (F) #58. Infection-enhancement activity to each DENV serotype was
determined by using FccR-expressing BHK cells and BHK cells by the formula: (mean plaque count at each serum dilution)/(mean plaque count in the
absence of human serum samples), and expressed as fold enhancement to DENV-2. Closed bars indicate FccR-expressing BHK cells and open bars
indicate FccR-negative BHK cells.
doi:10.1371/journal.pntd.0001536.g002
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cells, FccR-expressing CV-1 and BHK cells, and, DC-SIGN
expressing RAJI cells and U937 cells may better reflect the in vivo
neutralizing titers [40–46]. Surrogate plaque titration assays are,
however, required to determine virus titers in non-adherent
monocyte-lineage cells. Infection-enhancement was also detected
using an FccR-expressing cell line, THP-1 cells, for a subset of
serum samples (#39, 40, 28 and 77) which exhibited high
infection-enhancement activity to DENV-4 using FccR-expressing
BHK cells (data not shown). Thus, the results of ADE assays were
consistent between THP-1 cells and FccR-expressing BHK. In
addition, serum samples (#46, 40, 42, 43, 44, 45, 52 and 54) that
demonstrated neutralizing antibody titers to DENV-2 (1:10 to
.1:1280) along with neutralizing activities to other serotypes in
FccR-negative BHK cells exhibited neutralizing antibody only to
DENV-2 in FccR-expressing BHK cells. Cross-reactive neutral-
izing activity determined using FccR-negative cells was not
detected using FccR-positive cells. This could be due to hampered
neutralizing activity to heterologous serotypes by infection-
enhancing activity [25,42,47]. Importantly, our results suggest
that the FccR-expressing BHK cells provides more informative
data on serotype-specific neutralizing activity, and may better
reflect protection in vivo.
Presence of infection-enhancing activity in antibodies with
neutralizing activity to the infecting serotype has been reported
previously [37,38,47]. Interestingly, despite the result that 11 serum
samples from patients with DENV infection exhibited neutralizing
activity to the infecting serotype at 1:10–1:80 as determined by using
FccR-negative BHK cells, the neutralizing titer to the respective
infecting serotypes as determined by using FccR-expressing BHK
cells was ,1:10 in all of the 11 serum samples tested. It has been
reported that the main target cells of DENV infection in vivo are
FccR-expressingcells,suchas monocytesand macrophages[34–36].
The results suggest that DENV-antibody complexes which are
incapable of infecting FccR-negative cells, may retain the ability to
infect FccR-expressing cells due to the presence of FccR. However,
further studies are required to identify the relationship between
infection-enhancing activity and neutralizing activity during infec-
tion in vivo.
All four DENV serotypes are found co-circulating in Malaysia.
Although data was not available for the pre-dominant dengue
virus serotype in Perak prior to 2008, DENV-2 was the dominant
circulating serotype in peninsular Malaysia between 1998–2000
and 2006–2007 (Chua et al., unpublished data). High levels of
neutralizing activity against DENV-2 were detected in some of the
serum samples (Table 3), indicate that these individuals may have
been previously exposed to DENV-2. Previous studies have
suggested that ADE activity influences disease severity in patients
with secondary DENV infection [32,48]. As low levels of serum
dilutions may better reflect in vivo conditions, serum samples at
dilutions of 1:10 were used in the present study. The results
showed infection-enhancing activity (fold enhancement) of 0.7–6.7
to the infecting serotype at serum dilutions of 1:10. The assay
using FccR-expressing BHK cells detected infection-enhancing
activity to infecting serotypes at low serum dilutions in serum
samples with neutralizing activity, suggesting the presence of ADE
activity in vivo. Interestingly, there was an inverse relationship
between infection-enhancement activity to a DENV serotype and
high neutralizing activity as determined by using FccR-negative
BHK cells to the respective serotypes (Figure 2, Table 3, Table 4).
Previous studies showed that higher dilutions of patient serum
samples, in quantities that are not sufficient to support neutral-
ization, enhance DENV infection [32,47]. Patient serum samples
#49, 58, 42, 45, and 54, require higher concentrations for
neutralization in the presence of FccR than in the absence of
FccR. In addition, serum samples #57, 23, 28, 30, 74, 77, and 78
exhibited similar neutralizing antibody titers in both FccR-
expressing BHK cells and FccR-negative BHK cells [25]. Some
antibodies may require lower threshold occupancy for neutraliza-
tion, and, thus, virus neutralization may occur at similar
concentrations both in FccR-negative and FccR-expressing cells.
Alternatively, binding of some antibodies may lead to DENV
conformational changes [49], and therefore, result in virus
neutralization both in the presence and absence of FccR, at
similar antibody concentrations. The FccR-expressing BHK cell-
based assay system is unique as antibody neutralizing activity
could be analyzed and compared simultaneously using one cell
line (BHK cell line) either in the absence or presence of FccRb ya
conventional plaque assay.
It is known that primary infection with one DENV serotype
induces long-term protection to infection with the same serotype
[50]. By using serum samples from a DENV-endemic area, we
demonstrated that infection-enhancing activity which was deter-
mined only by using FccR-expressing cells hampers neutralizing
activity that was determined using FccR-negative BHK cells.
Moreover, infection-enhancing activity was also detected in serum
samples with low or negative neutralizing activity that were
determined using FccR-negative BHK cells. Although in vitro
systems may not faithfully reflect all aspects of DENV infection in
vivo, the results suggest that as compared to the neutralizing
activity determined by FccR-negative cell culture system, the sum
of neutralizing and enhancing activity determined by the FccR-
expressing cells may better reflect protection to DENV infection in
vivo. Further studies are, however, needed to define the
relationship between protection and neutralizing titers determined
by using FccR-positive cells.
Supporting Information
Table S1 Levels of neutralizing and infection-enhancing activity
in serum samples obtained from 42 non-acute dengue patients
against each of the four dengue virus serotypes.
(DOC)
Table S2 Absence of neutralizing and infection-enhancing
activities of serum samples obtained from 13 non-acute dengue
patients against each of the four dengue virus serotypes.
(DOC)
Table S3 Levels of neutralizing and infection-enhancing activ-
ities of serum samples obtained from seven DENV-1 patients and
eleven DENV-3 patients against each of the four dengue virus
serotypes.
(DOC)
Table S4 Absence of neutralizing and infection-enhancingactivity
in serum samples obtained from 5 acute primary DENV-1 dengue
patients and 2 acute primary DENV-3 patients against each of the
four dengue virus serotypes.
(DOC)
Table S5 Levels of enhancement activity against four DENV
serotypes in serum samples from patients with acute DENV-1 and
DENV-3 infection in comparison with those in samples from
patients with non acute DENV infection at 1:10 serum dilution as
determined by using FccR-expressing BHK cells.
(DOC)
Table S6 Levels of neutralizing activity against four DENV
serotypes in serum samples from patients with acute DENV-1 and
DENV-3 infection in comparison to those from patients with non-
ADE Activity in Sera with Neutralizing Activity
www.plosntds.org 7 February 2012 | Volume 6 | Issue 2 | e1536acute DENV infection, at 1:10 dilution, as determined by using
FccR-negative BHK cells.
(DOC)
Acknowledgments
We would like to thank the staff of National Public Health Laboratory,
Ministry of Health, Malaysia, for their efforts in obtaining and processing
the serum samples. We would also like to thank Mr. Akira Kotaki and Ms.
Makiko Ikeda for their excellent technical support.
Author Contributions
Conceived and designed the experiments: MLM IK. Performed the
experiments: MLM. Analyzed the data: MLM TT IK. Contributed
reagents/materials/analysis tools: CKL KBC TT. Wrote the paper: MLM
KBC TT IK.
References
1. World Health Organization (2009) Dengue: Guidelines for diagnosis, treatment,
prevention and control. whqlibdoc.who.int/publications/2009/9789241547871_eng.
pdf.
2. Srikiatkhachorn A, Gibbons RV, Green S, Libraty DH, Thomas SJ, et al. (2010)
Dengue hemorrhagic fever: the sensitivity and specificity of the world health
organization definition for identification of severe cases of dengue in Thailand,
1994–2005. Clin Infect Dis 50: 1135–1143.
3. Barrera R, Delgado N, Jime ´nez M, Valero S (2002) Eco-epidemiological factors
associated with hyperendemic dengue haemorrhagic fever in Maracay City,
Venezuela. Dengue Bull 26: 84–95.
4. Lai PC, Lee SS, Kao CH, Chen YS, Huang CK, et al. (2004) Characteristics of
a dengue hemorrhagic fever outbreak in 2001 in Kaohsiung. J Microbiol
Immunol Infect 37: 266–270.
5. Dengue Net-WHO Internet-based system for global surveillance of dengue fever
and dengue haemorrhagic fever (dengue/DHF). http://apps.who.int/globala-
tlas/default.asp.
6. Department of Health, Malaysia (2011) (In Malay) Press release: Dengue fever
and chikungunya. http://www.moh.gov.my/pr_categories/1/press_releases.
7. Abu Bakar S, Wong PF, Chan YF (2002) Emergence of dengue virus type 4
genotype IIA in Malaysia. J Gen Virol 83: 2437–2442.
8. Wong SS, Abdul Jamil J, Abu Bakar S (2007) Antibody neutralization and viral
virulence in recurring dengue virus type 2 outbreaks. Viral Immunol 20:
359–367.
9. Fan WF, Yu SR, Cosgriff TM (1989) The reemergence of dengue in China. Rev
Infect Dis Suppl 4: S847–853.
10. Shu PY, Chien LJ, Chang SF, Su CL, Kuo YC, et al. (2005) Fever screening at
airports and imported dengue. Emerg Infect Dis 11: 460–462.
11. Zheng K, Zhou HQ, Yan J, Ke CW, Maeda A, et al. (2009) Molecular
characterization of the E gene of dengue virus type 1 isolated in Guangdong
province, China, in 2006. Epidemiol Infect 137: 73–78.
12. Guzma ´n MG, Kouri G, Valdes L, Bravo J, Alvarez M, et al. (2000)
Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am J Epidemiol
152: 793–799.
13. Kosasih H, Yusuf H, Sudjana P, Alisjahbana B, Wuryadi S, et al. (2006) Report
of four volunteers with primary, secondary and tertiary dengue infections during
a prospective cohort study. Dengue Bull 30: 87–92.
14. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S,
et al. (1984) Risk factors in dengue shock syndrome: a prospective epidemiologic
study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120: 653–669.
15. Alvarez M, Rodriguez-Roche R, Bernardo L, Va ´zquez S, Morier L, et al. (2006)
Dengue hemorrhagic fever caused by sequential dengue 1–3 virus infections over
a long time interval: Havana epidemic, 2001–2002. Am J Trop Med Hyg 75:
1113–1117.
16. Tee HP, How SH, Jamalludin AR, Safhan MN, Sapian MM, et al. (2009) Risk
factors associated with development of dengue haemorrhagic fever or dengue
shock syndrome in adults in Hospital Tengku Ampuan Afzan Kuantan.
Med J Malaysia 64: 316–20.
17. Fried JR, Gibbons RV, Kalayanarooj S, Thomas SJ, Srikiatkhachorn A, et al.
(2010) Serotype-specific differences in the risk of dengue hemorrhagic fever: an
analysis of data collected in Bangkok, Thailand from 1994 to 2006. Plos Negl
Trop Dis 4: e617.
18. Modhiran N, Kalayanarooj S, Ubol S (2010) Subversion of innate defenses by
the interplay between DENV and pre-existing enhancing antibodies: TLRs
signaling collapse. PLoS Negl Trop Dis 4: e924.
19. Ubol S, Phuklia W, Kalayanarooj S, Modhiran N (2010) Mechanisms of immune
evasion induced by a complex of dengue virus and preexisting enhancing
antibodies. J Infect Dis 201: 923–935.
20. Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, et al.
(2011) An in-depth analysis of original antigenic sin in dengue virus infection.
J Virol 85(1): 410–421.
21. Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I (2011) Detection of higher
levels of dengue viremia using FccR-expressing BHK-21 cells than FccR-
negative cells in secondary Infection but not in primary infection. J Infect Dis
203: 1405–1414.
22. Klomporn P, Panyasrivanit M, Wikan N, Smith DR (2011) Dengue infection of
monocytic cells activates ER stress pathways, but apoptosis is induced through
both extrinsic and intrinsic pathways. Virology 409(2): 189–197.
23. Kou Z, Lim JY, Beltramello M, Quinn M, Chen H, et al. (2011) Human
antibodies against dengue enhance dengue viral infectivity without suppressing
type I interferon secretion in primary human monocytes. Virology 410:
240–247.
24. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, et al. (2009) A
prospective nested case-control study of dengue in infants: rethinking and
refining the antibody-dependent enhancement dengue hemorrhagic fever
model. PloS Med 6: e1000171.
25. Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I (2010) Discrepancy in
neutralizing antibody titers between plaque reduction neutralizing test using
FccR-negative and FccR-expressing BHK cells. Clin Vac Immunol 17:
402–407.
26. Cardosa MJ, Choo BH, Zuraini I (1992) A serological study of Japanese
encephalitis virus infections in northern Peninsular Malaysia. Southeast
Asian J Trop Med Public Health 22: 341–346.
27. Nayar SK, Noridah O, Paranthaman V, Ranjit K, Norizah I, et al. (2007) Co-
infection of dengue virus and chikungunya virus in two patients with acute
febrile illness. Med J Malaysia 62: 335–336.
28. Chin PS, Khoo AP, Asmah Hani AW, Chem YK, Norizah I, et al. (2008) Acute
dengue in a neonate secondary to perinatal transmission. Med J Malaysia 63:
265–256.
29. Ito M, Takasaki T, Yamada K, Nerome R, Tajima S (2004) Development and
evaluation of fluorogenic taqman reverse transcriptase PCR assays for detection
of dengue virus types 1 to 4. J Clin Microbiol 42: 5935–5937.
30. Moi ML, Takasaki T, Kotaki A, Tajima S, Lim CK, et al. (2010) Importation of
dengue virus type 3 to Japan from Tanzania and Co ˆte d’Ivoire. Emerg Infect Dis
16: 1770–1772.
31. Roehrig J (2007) Guidelines for plaque reduction neutralizing testing of human
antibodies to dengue viruses. World Health Organization. whqlibdoc.who.int/
hq/2007/who_ivb_07.07_eng.pdf.
32. Kliks S, Nisalak A, Brandt WE, Wahl L, Burke DS (1989) Antibody dependent
enhancement of dengue virus growth in human monocytes as risk factor for
dengue hemorrhagic fever. Am J Trop Med Hyg 40: 444–451.
33. Konishi E, Tabuchi Y, Yamanaka A (2010) A simple assay system for infection-
enhancing and -neutralizing antibodies to dengue type 2 virus using layers of
semi-adherent K562 cells. J Virol Methods 163: 360–367.
34. Blackley S, Kou Z, Chen H, Quinn M, Rose RC, et al. (2007) Primary human
splenic macrophages, but not T or B cells, are the principal target cells for
dengue virus infection in vitro. 81: 13325–13334.
35. Kou Z, Quinn M, Chen H, Rodrigo WW, Rose RC, et al. (2008) Monocytes,
but not T or B cells, are the principal target cells for dengue virus (DV) infection
among human peripheral blood mononuclear cells. J Med Virol 80: 134–146.
36. Boonnak K, Dambach KM, Donofrio GC, Tassaneetrithep B, Marovich MA
(2011) Cell type specificity and host genetic polymorphisms influence antibody-
dependent enhancement of dengue virus infection. J Virol 85(4): 1671–1683.
37. Laoprasopwattana K, Libraty DH, Endy TP, Nisalak A, Chunsuttiwat S, et al.
(2004) Dengue Virus (DV) enhancing antibody activity in preillness plasma does
not predict subsequent disease severity or viremia in secondary DV infection.
J Infect Dis 192: 510–519.
38. Hatch S, Endy TP, Thomas S, Mathew A, Potts J, et al. (2011) Intracellular
Cytokine Production by Dengue Virus-specific T cells Correlates with
Subclinical Secondary Infection. J Infect Dis 203: 1282–1291.
39. World Health Organization (2007) Guidelines for plaque reduction neutraliza-
tion testing of human antibodies to dengue viruses. http://whqlibdoc.who.int/
hq/2007/who_ivb_07.07_eng.pdf.
40. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, et
al. (2003) DC-SIGN (CD209) mediates dengue virus infection of human
dendritic cells. J Exp Med 197: 823–829.
41. Rodrigo WW, Jin X, Blackley SD, Rose RC, Schlesinger JJ (2006) Differential
enhancement of dengue virus immune complex infectivity mediated by
signaling-competent and signaling-incompetent human Fcgamma RIA (CD64)
or FcgammaRIIA (CD32). J Virol 80: 10128–38.
42. Rodrigo WW, Alcena DC, Kou Z, Kochel TJ, Porter KR, et al. (2009)
Difference between the abilities of human Fcgamma receptor-expressing CV-1
cells to neutralize American and Asian genotypes of dengue virus 2. Clin Vac
Immunol 16(2): 285–7.
43. Shanaka WW, Rodrigo I, Alcena DC, Rose RC, Jin X, et al. (2009) An
automated Dengue virus microneutralization plaque assay performed in human
Fc(gamma) receptor-expressing CV-1 cells. Am J Trop Med Hyg 80(1): 61–65.
44. Martin NC, Pardo J, Simmons M, Tjaden JA, Widjaja S, et al. (2006) An
immunocytometric assay based on dengue infection via DC-SIGN permits rapid
ADE Activity in Sera with Neutralizing Activity
www.plosntds.org 8 February 2012 | Volume 6 | Issue 2 | e1536measurement of anti-dengue neutralizing antibodies. J Virol Methods 134(1–2):
74–85.
45. Kraus Messer W, Haymore LB, de Silva AM (2007) Comparison of plaque- and
flow cytometry-based methods for measuring dengue virus neutralization. J Clin
Microbiol 45(11): 3777–3780.
46. Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ, et al. (2008) Role of
dendritic cells in antibody-dependent enhancement of dengue virus infection.
J Virol 82(8): 3939–3951.
47. Morens DM, Larsen LK, Halstead SB (1987) Study of the distribution of
antibody-dependent enhancement determinants on dengue 2 isolates using
dengue 2-derived monoclonal antibodies. J Med Virol 22: 163–7.
48. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, et al. (2004)
Relationship of preexisting dengue virus (DV) neutralizing antibody levels to
viremia and severity of disease in a prospective cohort study of DV infection in
Thailand. J Infect Dis 189: 990–1000.
49. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, et al.
(2008) Binding of a neutralizing antibody to dengue virus alters the arrangement
of surface glycoproteins. Nat Struct Mol Biol 15(3): 312–317.
50. Sabin AB (1952) Research on dengue fever during World War II. Am J Trop
Med Hyg 1: 30–50.
ADE Activity in Sera with Neutralizing Activity
www.plosntds.org 9 February 2012 | Volume 6 | Issue 2 | e1536